Canadian Adjuvant Initiative Workshop, March 26-27, 2013--Ottawa, Canada

Area of Science:

• Immunology and Vaccine Development
• Biotechnology and Pharmaceutical Sciences

Background:

• Novel adjuvants are essential for effective subunit vaccines against challenging diseases like chronic infections, intracellular pathogens, and cancer.
• Despite extensive research, the clinical translation of new adjuvants remains slow, hindering vaccine development.
• A Canadian Adjuvant Initiative Workshop convened stakeholders to address these challenges and foster collaboration.

Purpose of the Study:

• To stimulate discussion and identify innovation gaps in adjuvant development.
• To explore opportunities for networking and collaboration among industry, academia, and government.
• To facilitate the advancement of adjuvant research and development in Canada.

Main Methods:

• A two-day workshop was organized, bringing together Canadian and international experts in adjuvant research.
• Presentations covered diverse topics including industry criteria for adjuvant selection, discovery research, bioprocessing, veterinary vaccines, clinical trial capabilities, regulatory frameworks, and WHO formulation experience.
• Discussions focused on identifying unmet needs and potential solutions for accelerating adjuvant development.

Main Results:

• Key discussion points and innovation gaps in adjuvant development were identified.
• The workshop highlighted the need for improved bioprocessing, streamlined regulatory pathways, and enhanced clinical trial infrastructure.
• A consensus emerged on the opportunity to establish a Canadian Adjuvant Development Network.

Conclusions:

• The workshop successfully convened stakeholders to address critical issues in adjuvant development.
• Establishing a Canadian Adjuvant Development Network is proposed as a key step to facilitate research and clinical translation.
• Collaborative efforts are vital to overcome existing barriers and accelerate the delivery of novel adjuvant-based vaccines.